Epocrates prices initial public offering at $16.00 per share

Epocrates, Inc. (NASDAQ:EPOC) today announced the pricing of the initial public offering of 5,360,000 shares of its common stock at a price to the public of $16.00 per share. The shares are expected to begin trading today on the NASDAQ under the ticker symbol "EPOC." Epocrates is offering 3,574,285 shares and selling stockholders are offering the remaining 1,785,715 shares. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 804,000 shares of common stock from Epocrates to cover over-allotments, if any. Epocrates will not receive any proceeds from the sale of shares by the selling stockholders.

J.P. Morgan Securities LLC and Piper Jaffray & Co. are serving as joint book-running managers. William Blair & Company, L.L.C. and JMP Securities LLC are acting as co-managers.

A registration statement relating to this offering was declared effective by the Securities and Exchange Commission on February 1, 2011. This offering is being made solely by means of a written prospectus, a copy of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Ave, Edgewood, NY, 11717, or by calling 1-866-803-9204, or from Piper Jaffray & Co., 800 Nicollet Mall, Suite 800, Minneapolis, MN, 55402, or by calling 1-800-747-3924 or sending an email to [email protected].

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.